OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)
You may also be interested in...
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date